Zymeworks Inc. (ZYME) stock
ZYMENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 5/30667% above fair value
$26.04+0.20 (+0.77%)
Close on Nov 18, 2026Market cap $1.85BP/E –Yield –
Zymeworks free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Zymeworks's free cash flow for the twelve months ending Jun 30, 2026 was -$120.54M. For fiscal 2025 it was -$34.53M. The highest annual figure on record is $135.96M in fiscal 2022.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$34.53M | – |
| FY2024 | Dec 31, 2024 | -$112.05M | – |
| FY2023 | Dec 31, 2023 | -$120.80M | -188.8% |
| FY2022 | Dec 31, 2022 | $135.96M | – |
| FY2021 | Dec 31, 2021 | -$204.86M | – |
| FY2020 | Dec 31, 2020 | -$155.71M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$31.95M | -376.4% |
| Q1 FY2026 | Mar 31, 2026 | -$45.93M | – |
| Q4 FY2025 | Dec 31, 2025 | -$10.84M | – |
| Q3 FY2025 | Sep 30, 2025 | -$31.82M | – |
| Q2 FY2025 | Jun 30, 2025 | $11.56M | – |
| Q1 FY2025 | Mar 31, 2025 | -$3.42M | – |
| Q4 FY2024 | Dec 31, 2024 | -$41.82M | -408.1% |
| Q3 FY2024 | Sep 30, 2024 | -$6.78M | – |
| Q2 FY2024 | Jun 30, 2024 | -$25.59M | – |
| Q1 FY2024 | Mar 31, 2024 | -$37.86M | – |
| Q4 FY2023 | Dec 31, 2023 | $13.58M | -95.8% |
| Q3 FY2023 | Sep 30, 2023 | -$43.60M | – |
| Q2 FY2023 | Jun 30, 2023 | -$7.20M | – |
| Q1 FY2023 | Mar 31, 2023 | -$83.58M | – |
| Q4 FY2022 | Dec 31, 2022 | $327.01M | – |
| Q3 FY2022 | Sep 30, 2022 | -$74.00M | – |
| Q2 FY2022 | Jun 30, 2022 | -$57.49M | – |
| Q1 FY2022 | Mar 31, 2022 | -$59.57M | – |
| Q4 FY2021 | Dec 31, 2021 | -$55.29M | – |
See a number that looks wrong?